CD36 Variants Affect Lipid Levels and Early-Onset Coronary Disease

Impacts of CD36 Gene Variants on Plasma Lipid Levels

CD36 is a scavenger receptor primarily expressed in various tissues, including the heart, liver, and adipose tissue. It plays a crucial role in lipid uptake and metabolism. Variants of the CD36 gene, such as rs1761667, rs1049673, and rs3211956, have been shown to significantly influence plasma lipid profiles. In a systematic review and meta-analysis involving 25 studies with over 11,000 individuals, it was found that the A allele of rs1761667 was associated with elevated HDL-C levels and an increased risk of EOCAD, while the G alleles of rs1049673 and rs3211956 were linked to lower LDL-C levels and a reduced risk of EOCAD (Luo & Lv, 2025).

Table 1: Summary of CD36 Variants and Their Effects on Lipid Levels

The mechanisms through which these variants affect lipid levels primarily involve alterations in CD36 protein expression or function. For instance, the A allele of rs1761667 may inhibit CD36 expression, leading to dyslipidemia. On the other hand, rs1049673 and rs3211956 variants may enhance lipid metabolism, thereby reducing the risk of EOCAD.

Correlation Between CD36 Polymorphisms and EOCAD Risk

The link between CD36 variants and EOCAD has been established through various studies. The A allele of rs1761667 has been associated with an increased risk of developing EOCAD, particularly among Caucasian individuals. Conversely, the G alleles of rs1049673 and rs3211956 have been shown to decrease the risk of EOCAD in Chinese populations. The interaction between these genetic variants and environmental risk factors, such as hypertension and diabetes, plays a significant role in modifying the risk of EOCAD.

Table 2: Association of CD36 Variants with EOCAD Risk

The implications of these findings suggest that genetic screening for CD36 variants could be instrumental in early identification of individuals at high risk for EOCAD, enabling timely intervention and personalized treatment strategies.

Prevalence of CD36 Variants in Different Populations

The prevalence of CD36 variants varies significantly among different ethnic groups. For example, studies indicate that the A allele of rs1761667 is more common in Caucasian populations compared to Asian populations. This difference emphasizes the importance of considering genetic diversity when assessing CAD risk across different demographics.

Table 3: Prevalence of CD36 Variants by Ethnicity

Such variations highlight the need for population-specific studies to better understand the genetic factors contributing to EOCAD.

CD36’s Role in Lipid Metabolism and Coronary Health

CD36 functions as a receptor for various lipids, including oxidized LDL, and is involved in lipid uptake and transport. Its role in the pathogenesis of atherosclerosis is significant; CD36 mediates the uptake of fatty acids and oxidized lipoproteins by macrophages, leading to foam cell formation, a hallmark of atherosclerosis (Luo & Lv, 2025). Variants in CD36 can influence its expression and function, thereby affecting lipid metabolism and the overall risk for coronary artery disease.

Mechanisms of Action

1. Lipid Uptake: CD36 facilitates the uptake of long-chain fatty acids and oxidized LDL, influencing lipid accumulation in vascular tissues.
2. Inflammatory Response: CD36 activation in macrophages contributes to inflammatory processes, promoting atherosclerosis.
3. Regulation of Cholesterol Levels: CD36 variants can modulate cholesterol efflux and HDL metabolism, impacting overall cardiovascular health.

Recommendations for Genetic Screening in EOCAD Prevention

Given the significant association between CD36 variants and EOCAD risk, it is recommended that genetic screening for these variants be considered, particularly in populations with a high prevalence of these polymorphisms. Early identification of at-risk individuals based on their genetic profile may facilitate targeted interventions, lifestyle modifications, and medical therapies to mitigate the risk of EOCAD.

Potential Screening Protocols

1. Targeted Genetic Testing: Focus on rs1761667, rs1049673, and rs3211956 variants.
2. Comprehensive Risk Assessment: Integrate genetic data with traditional risk factors such as family history, smoking status, and metabolic syndrome indicators.
3. Lifestyle and Pharmacological Interventions: Tailor lifestyle recommendations and pharmacotherapy based on genetic risk factors.

FAQ Section

What is CD36 and why is it important?

CD36 is a scavenger receptor involved in lipid metabolism and is linked to the development of atherosclerosis and coronary artery disease.

How do CD36 variants affect lipid levels?

Specific variants in the CD36 gene can lead to altered protein expression, impacting lipid uptake and metabolism, which are crucial for maintaining cardiovascular health.

Why are different populations affected differently by CD36 variants?

Genetic diversity across populations can lead to varying prevalence and effects of CD36 variants, influencing the overall risk for diseases such as EOCAD.

What is EOCAD?

Early-onset coronary artery disease is defined as the initial manifestation of coronary artery disease occurring in men under 55 and women under 65 years old.

How can genetic screening help in preventing EOCAD?

Genetic screening for CD36 variants can identify individuals at higher risk for EOCAD, allowing for early interventions and personalized treatment strategies.

References

1. Luo, Z. & Lv, L. (2025). Impacts of CD36 Variants on Plasma Lipid Levels and the Risk of Early-Onset Coronary Artery Disease: A Systematic Review and Meta-Analysis. Cardiovascular Therapeutics

2. Touré, M., Hichami, A., Sayed, A., Suliman, M., Samb, A., Khan, N. A. (2022). Association between polymorphisms and hypermethylation of CD36 gene in obese and obese diabetic Senegalese females. Diabetology and Metabolic Syndrome. https://doi.org/10.1186/s13098-022-00881-2

3. Asch, A. S., Liu, I., Briccetti, F. M. (1993). Analysis of CD36 binding domains: ligand specificity controlled by dephosphorylation of an ectodomain. Science

4. Febbraio, M., Abumrad, N. A., Hajjar, D. P. (2000). A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. The Journal of Biological Chemistry. https://doi.org/10.1074/jbc.274.27.19055

5. Hegi, M. E., Diserens, A.-C., Gorlia, T. et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. New England Journal of Medicine

6. Biallelic variants of SEMA3F are associated with nonsyndromic hearing loss. (2025). Neoplasia. https://doi.org/10.1016/j.mocell.2025.100190

7. The ecology and geography of temnospondyl recovery after the Permian–Triassic mass extinction. (2025). Royal Society Open Science